Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) EPS (Basic) (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed EPS (Basic) for 9 consecutive years, with -$0.08 as the latest value for Q4 2024.

  • On a quarterly basis, EPS (Basic) rose 68.0% to -$0.08 in Q4 2024 year-over-year; TTM through Dec 2024 was -$0.52, a 61.76% increase, with the full-year FY2024 number at -$0.5, up 62.69% from a year prior.
  • EPS (Basic) was -$0.08 for Q4 2024 at SELLAS Life Sciences, up from -$0.1 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.08 in Q4 2024 to a low of -$1.05 in Q1 2022.
  • A 5-year average of -$0.38 and a median of -$0.34 in 2022 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): soared 95.2% in 2020, then crashed 556.25% in 2022.
  • SELLAS Life Sciences' EPS (Basic) stood at -$0.26 in 2020, then plummeted by 61.54% to -$0.42 in 2021, then fell by 2.38% to -$0.43 in 2022, then skyrocketed by 41.86% to -$0.25 in 2023, then soared by 68.0% to -$0.08 in 2024.
  • Per Business Quant, the three most recent readings for SLS's EPS (Basic) are -$0.08 (Q4 2024), -$0.1 (Q3 2024), and -$0.13 (Q2 2024).